Hippophae rhamnoides reverses decreased CYP2D6 expression in rats with BCG-induced liver injury

• Published in: Scientific reports Vol. 13; no. 1; p. 17425
• Main Authors: Zou, Huiqiong, Hao, Peipei, Cao, Yingying, Li, Li, Ding, Ruifeng, Bai, Xuefeng, Xue, Yongzhi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13-10-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 631/250/127/1213; 631/250/127/1220; 692/420/256; 692/420/256/2515; 692/699/249/2510; Cyclic AMP response element-binding protein; CYP2D6 protein; Cytochrome P450; Dextromethorphan; Down-regulation; Enzyme-linked immunosorbent assay; Hepatitis B; High-performance liquid chromatography; Hippophae rhamnoides; Humanities and Social Sciences; Liquid chromatography; Liver; Liver diseases; Metabolism; multidisciplinary; NF-κB protein; Protein kinase A; Proteomics; Recovery of function; Science; Science (multidisciplinary); Signal transduction; Tumor necrosis factor-α; Western blotting
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-44590-w

In this study, we investigated the effect of
Hippophae rhamnoides
L. (HRP) on the activity of CYP2D6 via the CAMP/PKA/NF-κB pathway in rats with Bacille Calmette–Guerin (BCG)-induced immunological liver injury. BCG (125 mg/kg) was injected to establish the rat model of liver injury. HRP was administered intragastrically for one week as the intervention drug. Proteomics techniques were used to analyze protein expression levels, obtaining a comprehensive understanding of the liver injury process. ELISA or western blotting was used to detect specific protein levels. Dextromethorphan was detected using high-performance liquid chromatography to reflect the metabolic activity of CYP2D6. BCG downregulated the expression of CYP2D6, cAMP, PKA, IκB, and P-CREB and upregulated that of NF-κB, IL-1β, TNF-α, and CREB in the liver; HRP administration reversed these effects. Therefore, HRP may restore the metabolic function of the liver by reversing the downregulation of CYP2D6 through inhibition of NF-κB signal transduction and regulation of the cAMP/PKA/CREB/CYP2D6 pathway. These findings highlight the role of HRP as an alternative clinical drug for treating hepatitis B and other immune-related liver diseases.